Interpace introduces ‘invaluable’ new lung cancer test
A new lung cancer test that differentiates between recurrences of the disease and newly formed instances has been praised as “invaluable” by doctors.
Interpace Diagnostics launched the test, MVPdX, this week and called it a “significant milestone” for the company, which provides clinically useful molecular diagnostic tests and pathology services.
Lung cancer causes the highest number of deaths for both men and women in the US, with over 220,000 per year. It also represents the second highest number of new cancer diagnoses for both men and women after prostate and breast cancer, respectively.
MVPdX compares the mutational fingerprint of two or more sites of lung cancer to determine whether the neoplastic deposits are representative of a recurrence of cancer or a new cancer.
Dr Jan F. Silverman of the Allegheny Health Network, said of MVPdX: “We have found this testing to be invaluable since it can affect the staging of the patient and treatment decisions.”
The test helps define the primary site of formation in relation to multiple sites of metastatic spread and helps differentiate multi-centric carcinoma from intra-organ spread of one cancer.
Jack E. Stover, president and CEO of Interpace Diagnostics, said: “This represents a significant milestone for the company as we expand our menu to include an entirely new vertical line of business in lung assays using our already proven technology.
“We believe this initiative will further diversify our product offering while potentially providing for further expansion of our revenues.”
Breaking down the numbers of lung cancer patients in the US, the American Cancer Society states that of the new cases each year, 116,990 are in men and 105,510 are in women.
About one in four US cancer deaths are from lung cancer with more people dying each year of lung cancer than from colon, breast, and prostate cancers combined.
About two thirds of those diagnosed with lung cancer are 65 or older, while less than 2% are younger than 45 and the average age at the time of diagnosis is about 70.
While the risk of getting lung cancer is much higher in smokers, in the overall population - both smokers and non-smokers - the chance that a man will develop lung cancer in his lifetime is about 1 in 14. For a woman, the risk is about 1 in 17.
NeuTigers: edge AI in healthcare
What is edge AI?
Edge AI is essentially a combination of edge computing and artificial intelligence. Algorithms are processed locally - directly on a mobile device or server - rather than in the cloud. This reduces cost, computing power and energy requirements. There are also claims that edge AI is so fast it is possible to reach near real-time analytics.
Edge AI devices include smart speakers, smart phones, laptops, robots, self-driven cars, drones, and surveillance cameras that use video analytics.
Who is NeuTigers?
NeuTigers is a spin-off company from Princeton University, formed in 2018 to apply edge AI and machine learning to solve challenges in healthcare, energy, productivity, and security.
With offices in Princeton, NJ, the company is based at one of the top AI accelerator programs of FutureLabs in New York, and has also established a subsidiary in Nice, France.
How is NeuTigers applying edge AI to healthcare?
The NeuTigers AI Technology Stack uses deep neural networks that mimic how the human brain perceives and interprets the world. The company has developed the StarDeepTM Smart Health Platform for health monitoring and biomedical imaging, to improve the accuracy and speed of diagnosing diseases.
NeuTigers say the platform has the potential to monitor and screen for thousands of conditions, when used in combination with medical devices and smart sensors already deployed in healthcare settings.
Are there any real world examples?
In January NeuTigers launched CovidDeep, a tool that predicts COVID-19 with more than 90% accuracy, using physiological data from a wristband along with blood pressure and blood oxygen readings. It then analyses the data and gives a prediction within two minutes.
This week NeuTigers announced a new study to detect the early signs of complications with sickle cell anaemia. Conducted at a hospital in Paris, the research will begin by looking at changes to skin response, heart beat, sleep and temperature to predict an acute episode of sickle cell anaemia, and how this impacts on the patients’ disease conditions and quality of life.
The second phase of the project is to expand with prospective studies across different sites in EU, Africa and the US to explore the models' accuracy and clinical effectiveness.
Adel Laoui, CEO and founder of NeuTigers, says: “The best way to deal with a crisis is to avoid it happening in the first place. We are now entering a new era where medical early warning systems have become a reality.
“We are excited at the possibility of deploying a technology that can save lives of patients dealing with sickle cell anaemia. The potential of the StarDeep platform to dramatically improve patient outcomes while slashing some of the highest costs of healthcare makes it one of the most exciting developments in preventative personal medicine.”